Replies to post #213091 on Biotech Values

[DewDiligence]

(ACHN/Medivir)—JNJ throws in the towel on HCV:

http://www.prnewswire.com/news-releases/janssen-to-discontinue-hepatitis-c-development-program-643657613.html

Janssen Sciences…today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir… This decision was made in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.

Inevitable and overdue.

Medivir (MVIR-B.ST) is down 8% today in Stockholm, implying that some investors didn’t realize JNJ’s HCV regimen was obsolete.